🇺🇸 FDA
Patent

US 10596259

Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof

granted A61KA61K38/05A61K41/0038

Quick answer

US patent 10596259 (Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof) held by The Regents of the University of California expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/05, A61K41/0038, A61K47/55, A61K47/64